EA038339B1 - Способы лечения аутизма - Google Patents

Способы лечения аутизма Download PDF

Info

Publication number
EA038339B1
EA038339B1 EA201792278A EA201792278A EA038339B1 EA 038339 B1 EA038339 B1 EA 038339B1 EA 201792278 A EA201792278 A EA 201792278A EA 201792278 A EA201792278 A EA 201792278A EA 038339 B1 EA038339 B1 EA 038339B1
Authority
EA
Eurasian Patent Office
Prior art keywords
tyrosine
methyl
administered
autism
subject
Prior art date
Application number
EA201792278A
Other languages
English (en)
Russian (ru)
Other versions
EA201792278A1 (ru
Inventor
Стивен Хоффман
Original Assignee
Стивен Хоффман
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/686,545 external-priority patent/US9308188B2/en
Priority claimed from US15/059,602 external-priority patent/US9763903B2/en
Application filed by Стивен Хоффман filed Critical Стивен Хоффман
Publication of EA201792278A1 publication Critical patent/EA201792278A1/ru
Publication of EA038339B1 publication Critical patent/EA038339B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
EA201792278A 2015-04-14 2016-03-28 Способы лечения аутизма EA038339B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/686,545 US9308188B2 (en) 2013-10-22 2015-04-14 Compositions and methods for treating intestinal hyperpermeability
US15/059,602 US9763903B2 (en) 2013-10-22 2016-03-03 Compositions and methods for treating intestinal hyperpermeability
PCT/US2016/024432 WO2016167944A2 (en) 2015-04-14 2016-03-28 Compositions and methods for treating intestinal hyperpermeability

Publications (2)

Publication Number Publication Date
EA201792278A1 EA201792278A1 (ru) 2018-04-30
EA038339B1 true EA038339B1 (ru) 2021-08-11

Family

ID=57126753

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792278A EA038339B1 (ru) 2015-04-14 2016-03-28 Способы лечения аутизма

Country Status (12)

Country Link
EP (2) EP4438059A3 (enExample)
JP (1) JP6858131B2 (enExample)
KR (1) KR20180015126A (enExample)
CN (1) CN107835695B (enExample)
AU (1) AU2016247301A1 (enExample)
BR (1) BR112017022184A2 (enExample)
CA (1) CA2982442A1 (enExample)
EA (1) EA038339B1 (enExample)
IL (1) IL254963A0 (enExample)
MX (1) MX2017013176A (enExample)
PH (1) PH12017501864A1 (enExample)
WO (1) WO2016167944A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
JP2021530568A (ja) * 2018-07-19 2021-11-11 ヤモ・ファーマシューティカルズ・エルエルシー 自閉症を処置するための組成物および方法
WO2020018292A1 (en) * 2018-07-19 2020-01-23 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
KR102726917B1 (ko) 2019-02-01 2024-11-07 닥터레이몬드 랩(주) 자폐증의 예측방법
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012165984A1 (en) * 2011-06-03 2012-12-06 Stowarzyszenie Św. Celestyna Clenbuterol for use in treatment of autism
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
WO2015061328A2 (en) * 2013-10-22 2015-04-30 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US20150216827A1 (en) * 2013-10-22 2015-08-06 Steven Hoffman Compositions and Methods for Treating Intestinal Hyperpermeability

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
WO2001078704A2 (en) * 2000-04-13 2001-10-25 Evans William T Gaba substrate and the use thereof for treating cognitive and emotional disorders
WO2006039691A2 (en) * 2004-10-01 2006-04-13 The Research Foundation Of State University Of New York Morphine and morphine precursors
US9949923B2 (en) * 2011-03-15 2018-04-24 Optinose As Nasal delivery
KR20190109564A (ko) * 2012-01-03 2019-09-25 큐어마크, 엘엘씨 신경계 및 정신 장애의 행동 증상을 치료하는 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012165984A1 (en) * 2011-06-03 2012-12-06 Stowarzyszenie Św. Celestyna Clenbuterol for use in treatment of autism
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
WO2015061328A2 (en) * 2013-10-22 2015-04-30 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US20150216827A1 (en) * 2013-10-22 2015-08-06 Steven Hoffman Compositions and Methods for Treating Intestinal Hyperpermeability

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANTHONY RUSSO: "Correlation Between Hepatocyte Growth Factor (HGF) and Gamma-Aminobutyric Acid (GABA) Plasma Levels in Autistic Children", BIOMARKER INSIGHTS, pages 69, XP055270234, DOI: 10.4137/BMI.S11448 *
LONGHURST, J.G. ; CARPENTER, L.L. ; EPPERSON, C. ; PRICE, L.H. ; MCDOUGLE, C.J.: "Effects of catecholamine depletion with AMPT (alpha-methyl-para-tyrosine) in obsessive-compulsive disorder", BIOLOGICAL PSYCHIATRY, ELSEVIER SCIENCE, NEW YORK, NY; US, vol. 46, no. 4, 15 August 1999 (1999-08-15), NEW YORK, NY; US, pages 573 - 576, XP027200399, ISSN: 0006-3223 *
OSWALD BLOEMEN, M. DE KONING, E. BOOT, J. BOOIJ, T.A. VAN AMELSVOORT: "Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review", CENTRAL NERVOUS SYSTEM AGENTS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD., BUSSUM, NL, vol. 8, no. 4, 1 December 2008 (2008-12-01), NL, pages 249 - 256, XP055383916, ISSN: 1871-5249, DOI: 10.2174/187152408786848102 *

Also Published As

Publication number Publication date
PH12017501864A1 (en) 2018-03-05
JP6858131B2 (ja) 2021-04-14
KR20180015126A (ko) 2018-02-12
IL254963A0 (en) 2017-12-31
EP3283115C0 (en) 2024-06-12
WO2016167944A3 (en) 2017-08-10
JP2018511639A (ja) 2018-04-26
CN107835695B (zh) 2021-07-09
WO2016167944A8 (en) 2017-11-02
WO2016167944A2 (en) 2016-10-20
EP4438059A3 (en) 2025-01-01
EP4438059A2 (en) 2024-10-02
EP3283115B1 (en) 2024-06-12
CA2982442A1 (en) 2016-10-20
CN107835695A (zh) 2018-03-23
AU2016247301A1 (en) 2017-10-26
EA201792278A1 (ru) 2018-04-30
MX2017013176A (es) 2018-01-30
BR112017022184A2 (pt) 2018-07-03
EP3283115A2 (en) 2018-02-21

Similar Documents

Publication Publication Date Title
US9763903B2 (en) Compositions and methods for treating intestinal hyperpermeability
AU2020203101B9 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
US9308188B2 (en) Compositions and methods for treating intestinal hyperpermeability
CN107835695B (zh) 用于治疗自闭症的组合物和方法
US12453709B2 (en) Compositions and methods for treating autism
US10751313B2 (en) Compositions and methods for treating autism
US12150924B2 (en) Compositions and methods for treating autism
JP2021530569A (ja) 自閉症を処置するための組成物および方法
HK40116464A (en) Compositions and methods for treating intestinal hyperpermeability